Literature DB >> 29165549

Prognostic impacts of Rho-kinase activity in circulating leucocytes in patients with vasospastic angina.

Taro Nihei1, Jun Takahashi1, Kiyotaka Hao1, Yoku Kikuchi1, Yuji Odaka1, Ryuji Tsuburaya1, Kensuke Nishimiya1, Yasuharu Matsumoto1, Kenta Ito1, Satoshi Miyata1, Yasuhiko Sakata1, Hiroaki Shimokawa1.   

Abstract

Aims: Rho-kinase activity in circulating leucocytes is a useful biomarker for diagnosis and disease activity assessment of vasospastic angina (VSA). The present study aimed to examine the long-term prognostic impact of Rho-kinase activity in circulating leucocytes in VSA patients. Methods and results: We prospectively enrolled 174 consecutive patients with VSA and 50 non-VSA patients, in whom we measured Rho-kinase activity in circulating leucocytes, and they were followed for a median of 16 months. The primary endpoint was cardiac events including cardiac death, non-fatal myocardial infarction, and hospitalization for unstable angina. During the follow-up period, cardiac events occurred in 10 VSA patients (5.7%) but in none of the non-VSA patients. When we divided VSA patients into two groups by a median value of their Rho-kinase activity, the Kaplan-Meier survival analysis showed a significantly worse prognosis in VSA patients with high Rho-kinase activity compared with those with low activity or non-VSA patients (log-rank; P < 0.05, respectively). Receiver-operating characteristic curve analysis showed that Rho-kinase activity value of 1.24 was the best cut-off level to predict cardiac events in VSA patients, and multivariable analysis showed that a value above the cut-off point had the largest hazard ratio to predict poor outcome in VSA patients [hazard ratio (95% confidence interval) 11.19 (1.41-88.95); P = 0.022]. Importantly, combination of the Japanese Coronary Spasm Association risk score and Rho-kinase activity significantly improved the prognostic impact in VSA patients as compared with either alone.
Conclusion: Rho-kinase activity in circulating leucocytes is useful for prognostic stratification of VSA patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29165549     DOI: 10.1093/eurheartj/ehx657

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  11 in total

Review 1.  circRNA is a potential target for cardiovascular diseases treatment.

Authors:  Jie Ju; Ya-Nan Song; Xin-Zhe Chen; Tao Wang; Cui-Yun Liu; Kun Wang
Journal:  Mol Cell Biochem       Date:  2021-11-15       Impact factor: 3.396

Review 2.  Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care.

Authors:  Hyon K Choi; Natalie McCormick; Chio Yokose
Journal:  Nat Rev Rheumatol       Date:  2021-12-17       Impact factor: 32.286

Review 3.  Circular RNAs: Promising Biomarkers for Human Diseases.

Authors:  Zhongrong Zhang; Tingting Yang; Junjie Xiao
Journal:  EBioMedicine       Date:  2018-08-02       Impact factor: 8.143

4.  Prognostic Impacts of Comorbid Significant Coronary Stenosis and Coronary Artery Spasm in Patients With Stable Coronary Artery Disease.

Authors:  Kiyotaka Hao; Jun Takahashi; Yoku Kikuchi; Akira Suda; Koichi Sato; Jun Sugisawa; Satoshi Tsuchiya; Tomohiko Shindo; Kensuke Nishimiya; Shohei Ikeda; Ryuji Tsuburaya; Takashi Shiroto; Yasuharu Matsumoto; Satoshi Miyata; Yasuhiko Sakata; Satoshi Yasuda; Hiroaki Shimokawa
Journal:  J Am Heart Assoc       Date:  2021-01-16       Impact factor: 5.501

Review 5.  Endothelium in Coronary Macrovascular and Microvascular Diseases.

Authors:  Shigeo Godo; Jun Takahashi; Satoshi Yasuda; Hiroaki Shimokawa
Journal:  J Cardiovasc Pharmacol       Date:  2021-12-03       Impact factor: 3.271

6.  Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group.

Authors:  Hiroaki Shimokawa; Akira Suda; Jun Takahashi; Colin Berry; Paolo G Camici; Filippo Crea; Javier Escaned; Tom Ford; Eric Yii; Juan Carlos Kaski; Takahiko Kiyooka; Puja K Mehta; Peter Ong; Yukio Ozaki; Carl Pepine; Ornella Rimoldi; Basmah Safdar; Udo Sechtem; Kenichi Tsujita; Satoshi Yasuda; John F Beltrame; C Noel Bairey Merz
Journal:  Eur Heart J       Date:  2021-11-21       Impact factor: 35.855

Review 7.  Coronary Vasospastic Angina: A Review of the Pathogenesis, Diagnosis, and Management.

Authors:  Rajan Rehan; James Weaver; Andy Yong
Journal:  Life (Basel)       Date:  2022-07-27

Review 8.  Treatment of coronary microvascular dysfunction.

Authors:  C Noel Bairey Merz; Carl J Pepine; Hiroki Shimokawa; Colin Berry
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 13.081

Review 9.  ROCK Inhibition as Potential Target for Treatment of Pulmonary Hypertension.

Authors:  Tadeu L Montagnoli; Jaqueline S da Silva; Susumu Z Sudo; Aimeé D Santos; Gabriel F Gomide; Mauro P L de Sá; Gisele Zapata-Sudo
Journal:  Cells       Date:  2021-06-30       Impact factor: 7.666

Review 10.  Microvascular Angina: Diagnosis and Management.

Authors:  Haider Aldiwani; Suzan Mahdai; Ghaith Alhatemi; C Noel Bairey Merz
Journal:  Eur Cardiol       Date:  2021-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.